Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
41.24
-2.28 (-5.24%)
At close: Nov 2, 2026, 4:00 PM EST
41.56
+0.32 (0.78%)
After-hours: Nov 2, 2026, 7:30 PM EST
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $267.95M in the quarter ending June 30, 2026, a decrease of -40.73%. This brings the company's total for the last twelve months to $874.09M, down -7.41% year-over-year. In the year 2025, Ionis Pharmaceuticals had annual revenue of $943.71M with 33.83% growth. That makes Ionis Pharmaceuticals the 8,267th largest company in the world by revenue and 1,872nd in the United States.
Revenue (ttm)
$874.09M
Revenue Growth
-7.41%
P/S Ratio
7.90
Revenue / Employee
$590,603
Employees
1,480
Market Cap
6.85B
Revenue by Segment
- Other 465.81M 49.4%
- SPINRAZA Royalties 212.30M 22.5%
- TRYNGOLZA 107.50M 11.4%
- WAINUA Royalties 49.10M 5.2%
- WAINUA Joint Development 42.10M 4.5%
- Other Commercial 35.00M 3.7%
- Other Royalties 24.10M 2.6%
- DAWNZERA 7.80M 0.8%
Fiscal year ended Dec 31, 2025 See the full Ionis Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 943.71M | 238.57M | 33.83% |
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 167.56M | 48.34% |
| Dec 31, 2016 | 346.62M | 62.92M | 22.18% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TG Therapeutics | 799.54M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Ligand Pharmaceuticals | 306.90M |
| Rhythm Pharmaceuticals | 239.92M |
| Praxis Precision Medicines | 7.46M |
| ABIVAX Société Anonyme | 5.33M |
IONS News
- 6 hours ago - Ionis to hold third quarter 2026 financial results webcast - Business Wire
- 10 days ago - Roche says Sefaxersen trial shows meaningful reduction in proteinuria - TheFly
- 10 days ago - Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) - Business Wire
- 11 days ago - Ionis ranked #1 on Science's Top Employers list - Business Wire
- 11 days ago - Ionis treatment of Dravet syndrome granted FDA orphan status - TheFly
- 12 days ago - 5-star BMO analyst upgrades Ionis ahead of Q3 report - TheFly
- 12 days ago - Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital - TheFly
- 12 days ago - 3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside - TipRanks